Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Core Insights - Curis, Inc. is hosting the 3rd Annual Symposium on IRAK4 in Cancer on September 26, 2024, focusing on the potential of IRAK4 inhibition in cancer treatment [1][2] - The symposium will present updated data for 10 evaluable patients in the PCNSL study, with ongoing patient enrollment expected to reach 15-20 by year-end [3][4] - Emavusertib, an orally available IRAK4 inhibitor, is currently in clinical trials for various hematologic malignancies and has received Orphan Drug Designation from the FDA and European Commission [6] Company Overview - Curis, Inc. specializes in the development of emavusertib, which is being tested in multiple Phase 1/2 studies for conditions such as relapsed/refractory primary central nervous system lymphoma (PCNSL) and acute myeloid leukemia (AML) [6] - The company has an exclusive license for emavusertib through a collaboration with Aurigene and has previously licensed rights to Erivedge® to Genentech for advanced basal cell carcinoma treatment [6] Symposium Details - The symposium will feature prominent experts in oncology, including Dr. Eric S. Winer and Dr. Grzegorz S. Nowakowski, discussing the biology of the IRAK4 pathway and its implications for cancer therapies [2][5] - The event is free and open to the public, aiming to foster discussion on the advancements in IRAK4 inhibition and its future development opportunities [1][2]